Evidence map›Paper›PMID 41385587›Full record

ArticlePLoS pathogens2025

Alternative polyadenylation upon CPSF6 knock-out enhances HIV-1 infection in primary T cells.

Daphne Cornish, Kathryn A Jackson-Jones, Ted Ling-Hu, Lacy M Simons, William J Cisneros, Edmund Osei Kuffour, Natalie Stegman, Francesca Agnes, Yujin Lee, Ved P Sharma and 3 more

Abstract read
In one paragraph

Article in PLoS pathogens, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Daphne CornishDivision of Infectious Diseases, Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States of America.ORCID 0000-0003-3835-5694
Kathryn A Jackson-JonesDivision of Infectious Diseases, Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States of America.
Ted Ling-HuDivision of Infectious Diseases, Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States of America.
Lacy M SimonsDivision of Infectious Diseases, Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States of America.
William J CisnerosDivision of Infectious Diseases, Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States of America.
Edmund Osei KuffourLaboratory of Retrovirology, The Rockefeller University, New York, New York, United States of America.
Natalie StegmanDivision of Infectious Diseases, Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States of America.
Francesca AgnesDivision of Infectious Diseases, Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States of America.
Yujin LeeDivision of Infectious Diseases, Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States of America.
Ved P SharmaBio-Imaging Resource Center, The Rockefeller University, New York, New York, United States of America.
Paul D BieniaszLaboratory of Retrovirology, The Rockefeller University, New York, New York, United States of America.
Ramon Lorenzo-RedondoDivision of Infectious Diseases, Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States of America.
Judd F HultquistDivision of Infectious Diseases, Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States of America.ORCID 0000-0001-6424-4280

Funding

Virology and Immunology Technology CoreP30AI117943 · NIAID · NORTHWESTERN UNIVERSITY AT CHICAGO · PI Mohamed Abdel Mohsen · 2015 to 2026
$38.4M
Project 3U54AI170792 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Alexander Marson · 2022 to 2026
$35.7M
Unraveling the Mechanisms of HIV Persistence and ReboundP01AI169600 · NIAID · NORTHWESTERN UNIVERSITY AT CHICAGO · PI Thomas Hope · 2022 to 2026
$9.3M
Functionally Defining HIV-Host Interactions During the Early HIV-1 LifecycleR01AI150998 · NIAID · NORTHWESTERN UNIVERSITY AT CHICAGO · PI BIENIASZ, PAUL D., HOPE, THOMAS · 2020 to 2024
$6.8M
Role of myeloid cells in CNS and systemic reservoirs and reboundR01MH125778 · NIMH · NORTHWESTERN UNIVERSITY AT CHICAGO · PI Thomas Hope, Ramon Lorenzo-Redondo · 2022 to 2026
$5.1M
Turning off HIV White Noise: Switching from Long-Lived to Short-Lived ReservoirR01AI176599 · NIAID · NORTHWESTERN UNIVERSITY AT CHICAGO · PI Elena Martinelli · 2023 to 2026
$4.7M
Regulation of SAMHD1 antiviral activityR01AI150455 · NIAID · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI DIAZ-GRIFFERO, FELIPE · 2019 to 2024
$3.3M
Deciphering the Role of CPSF6 in HIV InfectionR01AI165236 · NIAID · NORTHWESTERN UNIVERSITY AT CHICAGO · PI HULTQUIST, JUDD F · 2021 to 2025
$2.0M
Controlling HIV latency by manipulating CycT1 turnoverR01AI167778 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI FUJINAGA, KOH · 2022 to 2025
$1.6M
Donor-specific anti-HIV/SIV immunity mediated by APOBEC3 enzymesR56AI174877 · NIAID · TEXAS BIOMEDICAL RESEARCH INSTITUTE · PI EBRAHIMI, DIAKO · 2023 to 2023
$833k
A Functional Genomics Platform for the de novo Identification of Disease-relevant AllelesR21TR005017 · NCATS · NORTHWESTERN UNIVERSITY AT CHICAGO · PI HULTQUIST, JUDD F · 2024 to 2025
$440k
Exploring Small Molecule Inhibitors of PAF1C as Novel HIV Latency Reversal AgentsR21AI174864 · NIAID · NORTHWESTERN UNIVERSITY AT CHICAGO · PI HULTQUIST, JUDD F, SHILATIFARD, ALI · 2023 to 2024
$426k
NCATS NIH HHS R21 TR005017NIAID NIH HHS P01 AI169600NIAID NIH HHS P30 AI117943NIAID NIH HHS R01 AI150455NIAID NIH HHS R01 AI150998NIAID NIH HHS R01 AI165236NIAID NIH HHS R01 AI167778NIAID NIH HHS R01 AI176599NIAID NIH HHS R21 AI174864NIAID NIH HHS R56 AI174877NIAID NIH HHS U54 AI170792NIMH NIH HHS R01 MH125778
6 · The paper itself

Abstract

Human immunodeficiency virus (HIV) relies upon a broad array of host factors in order to replicate and evade the host antiviral response. Cleavage and polyadenylation specificity factor 6 (CPSF6) is one such host factor that is recruited by incoming HIV-1 cores to regulate trafficking, nuclear import, uncoating, and integration site selection. Despite these well-described roles, the impact of CPSF6 perturbation on HIV-1 infectivity varies considerably by cell type. Here, we report that CPSF6 knock-out in primary CD4+ T cells leads to increased permissivity to HIV-1 infection due to broad transcriptional reprogramming. Knock-out of CPSF6 results in widespread differential gene expression, including downregulation of genes involved in the innate immune response and enhanced expression of the HIV-1 co-receptors. Accordingly, these cells are less responsive to interferon and express lower levels of antiretroviral restriction factors, including TRIM5α. These transcriptional changes are linked to global shortening of mRNA 3' untranslated regions (UTRs) through changes in alternative polyadenylation (APA), which are triggered by disruption of the CPSF6-containing Cleavage Factor Im (CFIm) complex. Furthermore, we find that recruitment of CPSF6 by HIV-1 cores is sufficient to perturb CPSF6 function, leading to 3' UTR shortening and subsequent transcriptional rewiring. These results suggest a model in which HIV-1 transcriptionally reprograms target cells through recruitment of CPSF6 to incoming cores to circumvent the antiviral response and enhance permissivity to infection.

Indexed as

CD4-Positive T-LymphocytesHIV-1HIV InfectionsmRNA Cleavage and Polyadenylation FactorsPolyadenylationCells, CulturedHumanscleavage factor Im, humanmRNA Cleavage and Polyadenylation Factors

Identifiers

PMID41385587
PMCPMC12714223

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.